Sometimes the best investment opportunities hide in plain sight, masked by short-term concerns. That might be the case with Apellis Pharmaceuticals Inc. (APLS), which just released data that reinforces its star drug's long-term potential, even as Wall Street seems focused on near-term headwinds.
On Wednesday, the company unveiled results from a post hoc analysis of its GALE extension study, tracking patients who've been on Syfovre (pegcetacoplan injection) for five straight years. Syfovre treats geographic atrophy (GA), a progressive form of age-related macular degeneration that gradually destroys central vision.
The Numbers Tell a Compelling Story
Here's what matters: both dosing regimens of Syfovre delayed GA lesion growth by roughly 1.5 years in patients with nonsubfoveal GA compared to sham treatment. That's not a marginal improvement. That's meaningful preservation of vision for patients facing a degenerative disease.
Breaking it down further, patients on monthly pegcetacoplan saw a 31% reduction in lesion growth over 60 months versus projected sham. Those on the every-other-month regimen experienced a 27% reduction. Translated into real time, we're talking about slowing disease progression by approximately 16.5 to 18.5 months.
William Blair analyst Lachlan Hanbury-Brown notes these results align closely with the four-year analysis, which showed 32% and 27% reductions respectively. The consistency matters because it demonstrates durable efficacy, not just a temporary effect that fades over time.
The Market Disconnect
Here's where things get interesting. Despite showing strong clinical performance and posting third-quarter U.S. net product revenue of $150.9 million with 4% quarter-over-quarter growth in total injection demand, Apellis stock has been languishing.
William Blair points to the culprit: lack of copay assistance has constrained Syfovre growth, even as the company's Empaveli launch in C3G/IC-MPGN (a rare kidney disease) has shown promising momentum. The analyst's take? This weakness represents a buying opportunity.
The firm's reasoning centers on competitive dynamics. Hanbury-Brown argues that Syfovre holds blockbuster potential in the GA market over the long term because its superior efficacy versus competitor Astellas Pharma Inc.'s (ALPMF) Izervay (avacincaptad pegol) should eventually drive substantial market share gains as physicians shift their focus beyond safety concerns.
And there's evidence this transition is already underway. Syfovre has maintained resilient new patient share over the past year, suggesting doctors are increasingly prioritizing efficacy in their treatment decisions.
A Value Proposition
Perhaps the most striking detail: Apellis trades at an enterprise value of less than 3 times its 2025 revenue estimate. William Blair characterizes this as a "value disconnect," arguing that investors are fixating on near-term competitive pressure while overlooking the drug's long-term trajectory.
The firm maintains an Outperform rating on the stock, which closed Wednesday up 2.52% at $20.01. Whether the market will reward patience remains to be seen, but the five-year data suggests Syfovre's staying power might be stronger than its current valuation implies.